Medigen Vaccine Biologics (6547) — Cash Flow Quality Index
Medigen Vaccine Biologics (6547) has a Cash Flow Quality Index of -4.08x as of June 2026. Operating cash flow of NT$-91.20 Million is below net income of NT$22.35 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Medigen Vaccine Biologics (6547) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Medigen Vaccine Biologics Cash Flow Quality Index (2021–2021)
Historical Cash Flow Quality Index for Medigen Vaccine Biologics across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 6547 cash flow conversion.
Annual Cash Flow Quality Index for Medigen Vaccine Biologics (2021–2021)
Year-by-year earnings quality comparison for Medigen Vaccine Biologics.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.41x | NT$579.89 Million | NT$1.41 Billion | — |